Potential AngioDynamics, Inc. (NASDAQ:ANGO) shareholders may wish to note that the CEO, President & Director, James Clemmer, recently bought US$121k worth of stock, paying US$6.03 for each share. Although the purchase only increased their holding by 4.4%, it is still a solid purchase in our view.

The Last 12 Months Of Insider Transactions At AngioDynamics

Notably, that recent purchase by James Clemmer is the biggest insider purchase of AngioDynamics shares that we've seen in the last year. That implies that an insider found the current price of US$6.14 per share to be enticing. That means they have been optimistic about the company in the past, though they may have changed their mind. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. The good news for AngioDynamics share holders is that insiders were buying at near the current price.

While AngioDynamics insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

AngioDynamics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Insider Ownership Of AngioDynamics

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data indicates that AngioDynamics insiders own about US$7.7m worth of shares (which is 3.1% of the company). We do generally prefer see higher levels of insider ownership.

So What Does This Data Suggest About AngioDynamics Insiders?

It's certainly positive to see the recent insider purchases. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. While the overall levels of insider ownership are below what we'd like to see, the history of transactions imply that AngioDynamics insiders are reasonably well aligned, and optimistic for the future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 1 warning sign with AngioDynamics and understanding it should be part of your investment process.

Of course AngioDynamics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.